• Radiomedix

    Macrocyclics produces cGMP peptide in support of NET clinical trial

    November 1, 2016

    Macrocyclics was contracted by Radiomedix and AREVA Med to produce the cGMP peptide conjugate that will be used in their collaborative clinical trial. RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212 Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) — RadioMedix Inc. (Houston TX) and

    Read More
  • New Plano Facility on Schedule to Open in 2nd Quarter of 2016

    January 21, 2016

    AREVA Med’s second high-purity lead-212 (²¹²Pb) production facility is now well advanced in the construction and is expected to be operational, as scheduled, in the second quarter of 2016. Construction work began in September 2015 for this facility, known as the DDPU (Domestic Distribution and Purification Unit), which is located in Plano, Texas. This state-of-the-art

    Read More